监测骨质疏松症患者雷奈酸锶治疗情况。
Monitoring strontium ranelate therapy in patients with osteoporosis.
机构信息
University of British Columbia, Vancouver, BC, Canada.
出版信息
Osteoporos Int. 2009 Jul;20(7):1101-6. doi: 10.1007/s00198-009-0886-1. Epub 2009 Mar 6.
PURPOSE
The purpose of this study was to review the monitoring of strontium ranelate osteoporosis therapy.
METHODS
The method used in this study was comprehensive literature review with clinical perspectives.
RESULTS
Changes in bone turnover markers (BTM) or bone mineral density (BMD) have been documented in osteoporosis clinical trials. However, neither BMD nor BTM changes fully explain the observed fracture risk reduction in treated patients. If changes in BMD or BTM on therapy would be easily discernable in individual patients, and were strongly associated with fracture risk reduction, monitoring individuals would be more useful. BMD changes in patients on strontium ranelate are of a greater magnitude and hence can be easily determined in an individual patient. In addition, there exists a better correlation between fracture risk reduction and increases in BMD.
CONCLUSIONS
The strong correlation between measured BMD increases and fracture risk reduction in patients on strontium ranelate therapy will be of clinical benefit to physicians wishing to evaluate both treatment persistence and fracture risk reduction.
目的
本研究旨在回顾雷奈酸锶骨质疏松症治疗的监测。
方法
本研究采用的方法是具有临床观点的综合文献回顾。
结果
在骨质疏松症临床试验中已经记录了骨转换标志物（BTM）或骨密度（BMD）的变化。然而，BMD 或 BTM 的变化都不能完全解释治疗患者中观察到的骨折风险降低。如果治疗中 BMD 或 BTM 的变化在个体患者中容易辨别，并且与骨折风险降低有很强的相关性，那么监测个体将更有用。在接受雷奈酸锶治疗的患者中，BMD 的变化幅度更大，因此可以在个体患者中轻松确定。此外，BMD 增加与骨折风险降低之间存在更好的相关性。
结论
雷奈酸锶治疗患者的 BMD 增加与骨折风险降低之间的强相关性将对希望评估治疗持续性和骨折风险降低的医生具有临床益处。
Zotero 插件